Shares of iHuman Inc. (IH), a biopharmaceutical company focused on transforming medicines, skyrocketed 6.54% in pre-market trading on Monday. The surge came after the company reported impressive financial results for the fourth quarter and full year 2024, driven by strong sales of its flagship product Lumryz, and reaffirmed its 2025 guidance.

The key highlights that fueled the stock rally include a 158% year-over-year increase in Lumryz sales to $50.4 million in Q4 2024, taking the full-year total to $169.1 million. Additionally, iHuman reiterated its 2025 guidance, anticipating the number of patients on Lumryz to increase to 3,300-3,500 by year-end, generating net product revenue of $240-$260 million and positive cash flow of $20-40 million.

iHuman is executing multiple initiatives to accelerate patient demand for Lumryz, such as expanding its field sales team, doubling its reimbursement team, providing more direct support to patients and physicians, and adding patient ambassadors. The company is also making progress in its pivotal Phase 3 trial for idiopathic hypersomnia (IH), which could further solidify its leadership in sleep medicine.